Abstract
Aims:
This meta-analysis aimed to explore the association between serum uric acid levels and the efficacy of uric acid-lowering therapies on clinical outcomes among patients with heart failure with preserved ejection fraction (HFpEF).
Methods:
A comprehensive literature search was conducted through October 21, 2023, across PubMed, Embase, Cochrane Library, and Web of Science databases. The pooled effect sizes were estimated and presented with their respective 95% confidence intervals (CI). Subgroup analyses were conducted based on various factors, including sample size (<1,000 vs. ≥1,000), follow-up duration (<2 years vs. ≥2 years), study quality (assessed by a score of <7 vs. ≥7), ethnicity (Non-Asian vs. Asian), study design (prospective vs. retrospective), type of heart failure (HF) (acute vs. chronic), presence of hyperuricemia (yes or no), left ventricular ejection fraction (LVEF) thresholds (≥45% vs. ≥50%), and the type of uric acid-lowering therapy (traditional vs. novel).
Results:
The analysis included a total of 12 studies. Elevated serum uric acid levels were significantly linked to an increased risk of all-cause mortality [relative risk (RR): 1.21, 95% CI: 1.06–1.37, P = 0.004] and cardiovascular (CV) mortality (RR: 1.71, 95% CI: 1.42–2.04, P < 0.001) in HFpEF patients. Subgroup analyses confirmed this association, particularly in non-Asian populations, those with chronic HFpEF, and studies with a follow-up duration of two years or more. Additionally, higher uric acid levels were associated with an increased risk of HF-related hospitalization [hazard ratio (HR): 1.61, 95% CI: 1.12–2.34, P = 0.011]. Regarding treatment, uric acid-lowering therapy did not show a significant effect on reducing mortality in HFpEF patients. However, it was associated with a decreased risk of hospitalization due to HF (RR: 0.85, 95% CI: 0.79–0.91, P < 0.001).
Conclusion:
The findings of this study highlight the prognostic significance of serum uric acid levels in HFpEF and suggest that uric acid-lowering therapy may be beneficial in reducing the incidence of HF hospitalizations. Further research is warranted to elucidate the mechanisms by which uric acid-lowering therapy confers its potential benefits.
Introduction
Heart failure (HF) is a clinical syndrome resulting from injury and congestion of the heart with a considerable rate of morbidity, mortality, poor functional capacity and quality of life, and high costs (1). Patients with HF with preserved ejection fraction (HFpEF) [left ventricular ejection fraction (LVEF) ≥50%] comprise nearly half of those with chronic HF (2). The incidence and prevalence of HFpEF continue to rise in tandem with the increasing age and burdens of obesity, sedentariness, and cardio metabolic disorders (3). HFpEF affects up to 32 million people worldwide (4). Functional capacity and quality of life are severely impaired in HFpEF, and morbidity and mortality are high (5). Patients with HFpEF are hospitalized approximately 1.4 times per year and have an annual mortality rate of approximately 15% (4). Effective treatments for HFpEF are still lacking (6, 7), despite the inhibitors of sodium-glucose transport protein 2 (SGLT2) inhibitors, which have demonstrated positive effects on the prognosis of HFpEF patients (8, 9). Therefore, it is of great significance for disease management to investigate the prognostic factors of patients with HFpEF.
Uric acid, the end-product of purine metabolism in humans, is not only a cause of gout, but also may play a role in developing cardiovascular diseases (CVD) (10, 11). A systematic review and meta-analysis published in 2021 indicated that serum uric acid is positively associated with the risk of adverse events in chronic HF patients (12). Another systematic review and meta-analysis demonstrated that every 1 mg/dl reduction in uric acid was associated with a significantly lower risk of a composite of cardiovascular (CV) death and hospitalization for HF (13). Previous systematic reviews or meta-analyses have focused on the relationship between uric acid levels and the prognosis of HF patients. There has not yet been a meta-analysis examining the association between uric acid levels and the outcomes for patients with HFpEF. In addition, several studies have found a relationship between uric acid-lowering therapy and prognosis in HF. A systematic review and meta-analysis of clinical studies found that uric acid-lowering treatments increased all-cause and CV mortality (14). In a recent meta-analysis, targeting uric acid-lowering did not improve the prognosis of patients with HF (15). In view of the conflicting results and the lack of meta-analysis on the outcome of uric acid-lowering therapy in patients with HFpEF, a meta-analysis is warranted.
Herein, this meta-analysis aims to investigate the relationship between serum uric acid levels and the therapeutic impact of uric acid-lowering therapy on the clinical outcomes of patients with HFpEF. This meta-analysis may contribute to the management of patients with HFpEF.
Methods
This study followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (16).
Search methods for identification of studies
From inception to October 21, 2023, PubMed, Embase, Cochrane Library, and Web of Science databases were searched. English search terms include “serum uric acid” AND “urate lowering drug” AND “heart failure”. The search strategy of the PubMed database was shown in Supplementary Material Table S1. The retrieved literature was imported into EndNote20, where an initial screening was conducted by reviewing the titles and abstracts. Following this preliminary assessment, full texts of the screened literature were read to exclude studies that did not meet the inclusion criteria. Subsequently, the remaining literature was incorporated into this study. Search strategies were methodically executed by two independent researchers (Linzhi Li and Ying Chang), with any arising discrepancies resolved through consultation with a third author (Fei Li).
Eligibility criteria
Inclusion criteria were formulated based on the Population, Intervention, Comparator, Outcome, and Study design (PICOS) framework, encompassing: (1) P: patients with HFpEF; (2) I and C: serum uric acid levels/uric acid-lowering therapy; (3) O: all-cause mortality, CV mortality, HF hospitalization, and Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score; (3) S: cohort studies, and RCTs; (5) literature published in English.
Exclusion criteria: (1) animal experimental studies; (2) withdrawn studies; (3) reviews, meta-analyses, guidelines, consensus statements, errata, case reports, conference abstracts, editorial materials, letters, and trial registration records; (4) studies not relevant to the topic.
Data extraction
Two reviewers (Linzhi Li and Ying Chang) independently collected data from the selected studies. Data extracted from the included studies encompassed the first name of the author, year of publication, country, study design, sample size, age (years), sample size of male, LVEF (%), definition of higher uric acid level (mg/dl), follow-up, and outcome. In instances of discrepancy, consensus was reached by referring to a third investigator (Fei Li) for arbitration.
Assessment of quality of studies
The Newcastle-Ottawa Scale (NOS) (17) was used to assess the quality of cohort studies, with a total score of 9 points. Studies scoring 0–3 points were considered low quality, 4–6 points as medium quality, and 7–9 points as high quality. The Jadad scale (18) was utilized to evaluate the quality of RCTs, which comprises four items: generation of random sequences, allocation concealment, blinding (each item scoring up to 2 points), and withdrawals and dropouts (scoring 1 point). Studies scoring 1–3 points were deemed low quality, while those scoring 4–7 points were classified as high quality.
Statistical analysis
All data were analyzed using Stata 15.0 software. For categorical variables, the relative risk (RR) or hazard ratio (HR) was used as the effect size, while for continuous outcomes, the weighted mean difference (WMD) was employed. The results of the combined effect size were presented with the effect size and its 95% confidence interval (CI). Heterogeneity tests were conducted for each outcome measure, with a random-effects model analysis being performed if I2 ≥ 50%, and a fixed-effects model analysis otherwise. Subgroup analyses were carried out based on sample size (<1,000, and ≥1,000), follow-up duration (<2 years, and ≥2 years), literature quality (<7, and ≥7), ethnicity (Non-Asian, and Asian), study type (prospective, and retrospective), type of HF (acute, and chronic), hyperuricemia (yes, or no), LVEF (≥45%, or ≥50%), and the type of uric acid-lowering therapy used (traditional, or novel). Sensitivity analyses were conducted for all outcomes. When ten or more studies were included for outcomes, publication bias was assessed with funnel plot. A P value of <0.05 was considered statistically significant.
Results
Study selection process and characteristics of included studies
Initially, records were identified through various English databases: PubMed (n = 6,108), Web of Science (n = 9,266), Embase (n = 10,409), and the Cochrane Library (n = 364), totaling 26,147 records. A total of 10,824 duplicates were removed, leaving 15,323 records. These remaining records were then screened by title and abstract, resulting in the exclusion of 15,227 records. After exclusion, 96 full-text articles were assessed for eligibility. Finally, 12 (19–30) studies were included in the analysis. Figure 1 represents the literature screening process. The span of literature included in the study ranges from 2012 to 2023. Among the included articles, there were three RCTs and nine cohort studies. Six of the included articles were classified as high-quality studies. The shortest follow-up duration in the included literature was 12 weeks, while the longest was 4.81 years. Tables 1, 2 summarize the characteristics of the included studies.
Figure 1
Table 1
| Author | Year | Country | Study design | Sample size | Age | Male，n | LVEF (%) | Definition of higher UA level (mg/dl) | Follow-up | Adjustment variables | Univariate, HR (95% CI) | Multivariable, HR (95% CI) | Outcome | NOS, Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shimizu | 2015 | Japan | Prospective cohort | 424 | 68.36 ± 14.86 | 212 | 61.02 ± 9.10 | 7 | 897 days | Age, gender, systolic blood pressure, LVEF,B-type natriuretic peptide, presence of ischemic etiology, diabetes, atrial fibrillation, chronic kidney disease, anemia, hyperuricemia, and usage of blockers, renin-angiotensin-aldosterone system inhibitors, and diuretics | Cardiovascular mortality, 3.53 (1.35, 9.23); All-cause mortality, 2.08 (1.25, 3.46) | Cardiovascular mortality, 1.85 (0.58, 5.87); All-cause mortality, 1.98 (1.04, 3.79) | All-cause mortality Cardiovascular mortality | 5 |
| Selvaraj | 2020 | Multiple country | Prospective cohort | 4,795 | 72.71 ± 8.45 | 2,316 | 58 ± 8 | 66–90 years, men 8 women 7.3 18–65 years, women 6.9 | 4 months | Age, sex, race, region, systolic blood pressure, heart rate, ejection fraction, NYHA class, history of HF hospitalization, duration of HF, atrial fibrillation, diabetes, body mass index, prior myocardial infarction, prior stroke, estimated glomerular filtration rate, haemoglobin, sodium, albumin, randomized treatment, diuretic use and NT-proBNP | Cardiovascular mortality, 1.71 (1.40, 2.09); All-cause mortality, 1.56 (1.33, 1.82); HF hospitalization, 2.05 (1.72, 2.45) | Cardiovascular mortality,1.58 (1.26, 1.98); All-cause mortality, 1.42 (1.18, 1.69); HF hospitalization, 1.61 (1.34, 1.94) | All-cause mortality Cardiovascular mortality HF hospitalization | 7 |
| Nishino | 2022 | Japan | Prospective cohort | 464 | 81.81 ± 8.23 | 231 | 60.34 ± 7.85 | 7 | 480 days | NR | NR | NR | All-cause mortality HF hospitalization | 6 |
| Ambrosio | 2021 | Italy | Prospective cohort | 4,938 | 64.6 (13.20)* | 3,562 | 37.5 (13.48) | 6.61 | 18 months | NR | NR | NR | Cardiovascular mortality HF hospitalization | 7 |
| Carnicelli | 2020 | USA | Retrospective cohort | 7,004 | 68.16 ± 15.86 | 2,988 | NR | 6 | 2.6 years | Demographics (age, gender, and race),co-morbidities (diabetes, hypertension, and prior myocardial infarction), year of index echocardiogram (categorized), baseline measures (left ventricular ejection fraction, heart rate, systolic blood pressure, and body mass index), baseline medications (beta-blocker, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blockers, and loop diuretic), and baseline laboratory measures (sodium, hemoglobin, blood urea nitrogen, and creatinine) | All-cause mortality, 1.24 (1.13, 1.36); HF hospitalization, 1.27 (1.17, 1.38) | All-cause mortality, 0.98 (0.89, 1.08); HF hospitalization, 1.03 (0.94, 1.12) | All-cause mortality HF hospitalization | 6 |
| Deng | 2023 | China | Prospective cohort | 210 | 74 (67, 81)* | 86 | 61 (58, 65) | 7 | 278 days | Gender, NYHA class, coronary artery disease, atrial fibrillation, right ventricular dysfunction, NT-proBNP, and Cr | HF hospitalization, 2.98 (1.70, 5.21) | HF hospitalization, 3.03 (1.52–6.03) | HF hospitalization | 7 |
| Kobayashi | 2020 | Japan | Prospective cohort | 516 | 78 ± 11 | 256 | 60 ± 8 | 7.4 | 749 days | Age, male, systolic blood pressure, sodium, log brain natriuretic peptide, albumin, blood urea nitrogen, use of diuretics before admission | NR | All-cause mortality, 1.23 (1.10, 1.39) | All-cause mortality | 6 |
| Wang | 2023 | China | Retrospective cohort | 7,769 | 62.64 ± 15.12 | 6,244 | NR | 7 | 4.81 years | NR | NR | NR | All-cause mortality | 5 |
Basic information of literature on the association between uric acid and adverse outcomes of HF.
HF, heart failure; USA, United States of America; NR, non-reported; LVEF, left ventricular ejection fraction; UA, uric acid; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Cr, creatinine; HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Scale.
*Stands for median (IQR).
Table 2
| Author | Year | Country | Study design | Sample size | Age | Male, n | Follow-up | Adjustment variables | Univariate, HR (95% CI) | Multivariable, HR (95% CI) | Outcome | NOS, quality score | Jadad, quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Málek | 2012 | Czech Republic | Prospective cohort | 1,255 | 73.4 (45.7, 87.7)a | 714 | 2 years | NR | NR | NR | All-cause mortality | 6 | |
| Solomon | 2019 | Multiple country | RCT | 4,796 | 72.75 ± 8.40 | 2,317 | 35 months | NR | NR | NR | All-cause mortality Cardiovascular death HF hospitalization KCCQ-CS | 4 | |
| Nassif | 2021 | Multiple country | RCT | 324 | 70.35 ± 10.48 | 140 | 12 weeks | NR | NR | Cardiovascular mortality, 0.89 (0.70, 1.13); All-cause mortality, 1.02 (0.86, 1.21); HF hospitalization, 0.78 (0.64, 0.95) | KCCQ-CS | 7 | |
| Nishino | 2022 | Japan | Prospective cohort | 291 | 81.5 ± 7.33 | 146 | 480 days | NR | NR | NR | All-cause mortality HF hospitalization | 6 | |
| Anker | 2022 | Multiple country | RCT | 4,005 | 72.8 ± 9.2 | 1,986 | 24 months | NR | NR | All-cause mortality, 1.63 (1.08, 2.45) | All-cause mortality Cardiovascular death HF rehospitalization | 4 |
Basic information of literature on the association between uric acid-lowering therapy and adverse outcomes of HF.
HF, heart failure; KCCQ-CS, Kansas City cardiomyopathy questionnaire clinical summary score; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; amedian (interquartile range); NR, non-reported; HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Scale.
Meta-analysis of the association between serum uric acid level and all-cause mortality in patients with HFpEF
High serum uric acid level vs. low serum uric acid level (RR)
A total of six studies were included to assess the association between serum uric acid levels and all-cause mortality in patients with HFpEF. Due to high heterogeneity, as indicated by an I2 of 87.2%, a random-effects model was utilized for the analysis. The pooled analysis suggested that elevated serum uric acid levels were associated with an increased risk of all-cause mortality in patients with HFpEF (RR: 1.21, 95% CI: 1.06–1.37, P = 0.004) (Figure 2A, Table 3). The subgroup analyses showed that in studies with a sample size of 1,000 or greater (RR: 1.28, 95% CI: 1.12–1.46, P < 0.001), in studies with a follow-up duration of 2 years or longer (RR: 1.17, 95% CI: 1.01–1.35, P = 0.037), regardless of whether the quality score was less than 7 or 7 and above, among non-Asian populations (RR: 1.16, 95% CI: 1.08–1.24, P < 0.001), in retrospective study designs (RR: 1.19, 95% CI: 1.11–1.28, P < 0.001), and among patients with chronic HF (RR: 1.25, 95% CI: 1.14–1.37, P < 0.001), elevated serum uric acid levels were significantly associated with increased all-cause mortality in patients with HFpEF (Table 3).
Figure 2
Table 3
| Outcomes | Indicators | RR/HR | P | I2 |
|---|---|---|---|---|
| Cardiovascular mortality (RR) | Overall | 1.71 (1.42, 2.04) | <0.001 | 15.9% |
| All-cause mortality (RR) | Overall | 1.21 (1.06, 1.37) | 0.004 | 87.2% |
| Sample size | ||||
| <1,000 | 1.12 (0.913, 1.37) | 0.279 | 79.3% | |
| ≥1,000 | 1.28 (1.12, 1.46) | <0.001 | 82.3% | |
| Follow-up | ||||
| <2 years | 1.28 (0.92, 1.77) | 0.144 | 87.0% | |
| ≥2 years | 1.17 (1.01, 1.35) | 0.037 | 91.3% | |
| Quality score | ||||
| <7 | 1.14 (1.02, 1.29) | 0.025 | 82.9% | |
| ≥7 | 1.51 (1.31, 1.74) | <0.001 | 0.0% | |
| Ethnicity | ||||
| Non-Asian | 1.16 (1.08, 1.24) | <0.001 | 0.0% | |
| Asian | 1.16 (0.98, 1.38) | 0.095 | 86.3% | |
| Study design | ||||
| Prospective | 1.26 (0.98, 1.60) | 0.070 | 91.1% | |
| Retrospective | 1.19 (1.11, 1.28) | <0.001 | 41.9% | |
| HF type | ||||
| Acute | 1.12 (0.91, 1.37) | 0.279 | 79.3% | |
| Chronic | 1.25 (1.14, 1.37) | <0.001 | 0.0% | |
| All-cause mortality (HR) | Overall | 1.20 (1.14, 1.25) | <0.001 | 0.0% |
| HF hospitalization (RR) | Overall | 1.42 (0.97, 2.09) | 0.070 | 97.9% |
| Sample size | ||||
| <1,000 | 1.03 (0.86, 1.23) | 0.749 | 0.0% | |
| ≥1,000 | 1.60 (0.99, 2.57) | 0.053 | 98.5% | |
| Follow-up | ||||
| <2 years | 1.56 (0.95, 2.58) | 0.082 | 95.4% | |
| ≥2 years | 1.12 (1.06, 1.18) | <0.001 | 0.0% | |
| Quality score | ||||
| <7 | 1.11 (1.05, 1.17) | <0.001 | 0.0% | |
| ≥7 | 1.99 (1.84, 2.16) | <0.001 | 0.0% | |
| Ethnicity | ||||
| Non-Asian | 1.39 (0.84, 2.32) | 0.203 | 81.9 | |
| Asian | 1.03 (0.86, 1.23) | 0.749 | 0.0% | |
| Study design | ||||
| Prospective | 1.56 (0.95, 2.58) | 0.082 | 95.4% | |
| Retrospective | 1.12 (1.06, 1.18) | <0.001 | 0.0% | |
| HF hospitalization (HR) | Overall | 1.61 (1.12, 2.34) | 0.011 | 90.8% |
| Sample size | ||||
| <1,000 | 1.70 (0.58, 4.95) | 0.332 | 89.4% | |
| ≥1,000 | 1.60 (1.00, 2.56) | 0.049 | 95.7% | |
| Follow-up | ||||
| <2 years | 1.80 (1.06, 3.07) | 0.031 | 83.9% | |
| ≥2 years | 1.27 (1.17, 1.38) | <0.001 | 0.0% | |
| Quality score | ||||
| <7 | 1.23 (1.06, 1.44) | 0.008 | 18.9% | |
| ≥7 | 2.24 (1.64, 3.06) | <0.001 | 36.1% | |
| Ethnicity | ||||
| Non-Asian | 1.27 (1.17, 1.38) | <0.001 | 0.0% | |
| Asian | 1.70 (0.58, 4.95) | 0.332 | 89.4% | |
| Study design | ||||
| Prospective | 1.80 (1.06, 3.07) | 0.031 | 83.9% | |
| Retrospective | 1.27 (1.17, 1.38) | <0.001 | 0.0% |
Meta-analysis of the association between serum uric acid level and outcomes in patients with HFpEF.
HFpEF, heart failure with preserved ejection fraction; HF, heart failure; RR, relative risk; HR, hazard ratio.
Per 1 mg/dl rise of serum uric acid level (HR)
Two studies were included for analysis between every 1 mg/dl rise in serum uric acid level and all-cause mortality in patients with HFpEF. Heterogeneity testing yielded an I2 of 0.0%, thus a fixed-effect model was employed for the analysis. The pooled analysis demonstrated that for each 1 mg/dl elevation in serum uric acid levels, the risk of all-cause mortality increased (HR: 1.20, 95% CI: 1.14–1.25, P < 0.001) (Figure 2B, Table 3).
Meta-analysis of the association between serum uric acid level and CV mortality in patients with HFpEF
High serum uric acid level vs. low serum uric acid level
Three studies were included to assess the association between serum uric acid level and CV mortality in patients with HFpEF. The fixed-effect model analysis suggested a significant association between increased serum uric acid levels and a higher risk of CV mortality (RR: 1.71, 95% CI: 1.42–2.04, P < 0.001) (Figure 3, Table 3).
Figure 3
Meta-analysis of the association between serum uric acid level and HF hospitalization in patients with HFpEF
High serum uric acid level vs. low serum uric acid level (RR)
Four studies assessed the association between serum uric acid level and HF hospitalization in patients with HFpEF, with heterogeneity testing showing an I2 of 97.9%. Consequently, analysis was conducted using a random-effects model. The outcome implied that elevated levels of serum uric acid did not have a significant correlation with HF hospitalization in patients with HFpEF (RR: 1.42, 95% CI: 0.97–2.09, P = 0.070) (Figure 4A, Table 3). However, subgroup analyses demonstrated that in contexts where the follow-up period extends to 2 years or longer, the studies were of a retrospective nature, and there was a notable association between increased uric acid levels and hospitalization for HF.
Figure 4
High serum uric acid level vs. low serum uric acid level (HR)
Four studies were included to examine the association between serum uric acid level (HR) and HF hospitalization in patients with HFpEF. The heterogeneity testing indicated an I2 of 90.8%, leading to the use of a random-effects model for analysis. The results suggested that an increase in uric acid levels was associated with an increased risk of hospitalization due to HF (HR: 1.61, 95% CI: 1.12–2.34, P = 0.011) (Figure 4B, Table 3). Subgroup analysis revealed that this relationship holds true across studies with a sample size of 1,000 or more, regardless of the duration of follow-up, the quality of the studies, whether the HF was acute or chronic, and also among non-Asian populations (Table 3).
Meta-analysis of the association between uric acid-lowering therapy and all-cause mortality in patients with HFpEF
Experimental vs. control (RR)
The analysis incorporated three studies to assess the association between uric acid-lowering therapy and all-cause mortality in patients with HFpEF, revealing no heterogeneity (I2 = 0.0%), and hence, a fixed-effect model was utilized. The results showed that lowering uric acid levels through treatment did not significantly alter the outcome for all-cause mortality in patients with HFpEF (RR: 0.97, 95% CI: 0.89–1.06, P = 0.532) (Figure 5A, Table 4). This conclusion remained consistent across subgroups defined by the presence of hyperuricemia, LVEF, and the type of uric acid-lowering therapy used (Table 4).
Figure 5
Table 4
| Outcomes | Indicators | RR/HR/WMD | P | I2 |
|---|---|---|---|---|
| Cardiovascular mortality | Overall | 0.92 (0.80, 1.07) | 0.274 | 0.0% |
| All-cause mortality (RR) | Overall | 0.97 (0.89, 1.06) | 0.532 | 0.0% |
| Hyperuricemia | ||||
| No | 0.98 (0.89, 1.09) | 0.746 | 0.0% | |
| Yes | 0.916 (0.82, 1.02) | 0.115 | 0.0% | |
| LVEF | ||||
| ≥45% | 0.97 (0.85, 1.12) | 0.693 | 87.0% | |
| ≥50% | 0.97 (0.87, 1.09) | 0.621 | 0.0% | |
| Uric acid-lowering drugs | ||||
| Traditional | 0.92 (0.82, 1.02) | 0.115 | 0.0% | |
| Novel | 0.98 (0.89, 1.09) | 0.746 | 0.0% | |
| All-cause mortality (HR) | Overall | 1.16 (0.93, 1.45) | 0.186 | 66.9% |
| Hyperuricemia | ||||
| No | 1.24 (0.79,1.95) | 0.351 | 76.6% | |
| Yes | 1.17 (0.61, 2.26) | 0.635 | 81.3% | |
| LVEF | ||||
| ≥45% | 0.97 (0.84, 1.13) | 0.687 | 0.0% | |
| ≥50% | 1.34 (0.92, 1.97) | 0.128 | 71.1% | |
| Uric acid-lowering drugs | ||||
| Traditional | 1.66 (1.20, 2.28) | 0.002 | 0.0% | |
| Novel | 0.99 (0.89, 1.11) | 0.877 | 0.0% | |
| HF hospitalization | Overall | 0.85 (0.79, 0.91) | <0.001 | 0.0% |
| Hyperuricemia | ||||
| No | 0.85 (0.78, 0.92) | <0.001 | 0.0% | |
| Yes | 0.83 (0.73, 0.94) | 0.003 | 0.0% | |
| LVEF | ||||
| ≥45% | 0.86 (0.79, 0.94) | <0.001 | 0.0% | |
| ≥50% | 0.81 (0.72, 1.18) | 0.002 | 0.0% | |
| Uric acid-lowering drugs | ||||
| Traditional | 0.85 (0.78, 0.92) | <0.001 | 0.0% | |
| Novel | 0.83 (0.73, 0.94) | 0.003 | 0.0% | |
| Change in KCCQ clinical summary score | Overall | 1.96 (−0.91, 4.84) | 0.181 | 60.3% |
Meta-analysis of the association between uric acid-lowering therapy and outcome in patients with HFpEF.
HFpEF, heart failure with preserved ejection fraction; HF, heart failure; RR, relative risk; HR, hazard ratio; WMD, weighted mean difference; LVEF, left ventricular ejection fraction; KCCQ: Kansas City cardiomyopathy questionnaire.
Experimental vs. control (HR)
The association between uric acid-lowering therapy and all-cause mortality in patients with HFpEF (HR) was analyzed in 4 studies. The heterogeneity testing resulted in an I2 of 66.9%, leading to the adoption of a random-effects model. The results indicated that uric acid-lowering therapy did not significantly reduce the risk of all-cause mortality (HR: 1.16, 95% CI: 0.93–1.45, P = 0.186) (Figure 5B, Table 4). Subgroup analysis revealed that only when uric acid-lowering medication was of the traditional type did the treatment increase the risk of all-cause mortality (HR:1.66, 95% CI: 1.20–2.28, P = 0.002) (Table 4).
Meta-analysis of the association between uric acid-lowering therapy and CV mortality in patients with HFpEF
Two studies were included to assess the association between uric acid-lowering therapy and CV mortality in patients with HFpEF. Heterogeneity testing showed an I2 of 0.0%, which led to the use of a fixed-effect model for analysis. The result indicated that uric acid-lowering therapy did not significantly improve the outcome of CV mortality (RR: 0.92, 95% CI: 0.80–1.07, P = 0.274) (Figure 6, Table 4).
Figure 6
Meta-analysis of the association between uric acid-lowering therapy and HF hospitalization in patients with HFpEF
A total of three studies were included to assess the association between uric acid-lowering therapy and HF hospitalization in patients with HFpEF. Heterogeneity testing revealed an I2 of 0.0%, hence a fixed-effect model was employed for analysis. The results suggested that uric acid-lowering therapy was associated with a lower risk of HF hospitalization (RR: 0.85, 95% CI: 0.79–0.91, P < 0.001) (Figure 7, Table 4). Subgroup analyses based on the presence of hyperuricemia, LVEF, and the type of uric acid-lowering therapy also yielded consistent results (Table 4).
Figure 7
Meta-analysis of the association between uric acid-lowering therapy and change in KCCQ clinical summary score
The analysis incorporated two studies to assess the association between uric acid-lowering therapy and change in KCCQ clinical summary score. Heterogeneity testing indicated an I2 of 60.3%, leading to the use of a random-effects model for the analysis. The results indicated that there was no significant difference in the change of the KCCQ clinical summary score between the uric acid-lowering therapy group and the control group (WMD: 1.964, 95% CI: −0.913 to 4.842, P = 0.181) (Figure 8, Table 4).
Figure 8
Sensitivity analysis
Sensitivity analysis in our study demonstrated the robustness of our findings. By systematically excluding certain studies and re-evaluating the effect estimates, we have ensured that our conclusions were not unduly influenced by any single study or potential biases. This rigorous examination of our data strengthens the reliability of our results and provides confidence in the validity of our research (Table 4).
Discussion
This study incorporated 12 eligible articles to separately explore the associations of serum uric acid levels and uric acid-lowering therapy with the prognosis of patients with HFpEF. The findings of this study reveal that elevated serum uric acid levels were consistently associated with an increased risk of all-cause mortality and CV mortality in HFpEF patients. Subgroup analyses further confirmed the association between serum uric acid levels and all-cause mortality, especially in non-Asian populations, those with chronic HFpEF, and when the follow-up duration was two years or longer. An increase in uric acid levels was also associated with an increased risk of hospitalization due to HF [hazard ratio (HR)]. In terms of therapeutic interventions, uric acid-lowering therapy did not significantly reduce mortality in patients with HFpEF. Nevertheless, uric acid-lowering therapy was associated with a reduced risk of HF hospitalization, indicating a potential benefit in managing this aspect of HFpEF prognosis.
Previous studies have illuminated that serum uric acid stands as a distinctive risk factor for HF and prognosis of HF (31–36). In a large Italian cohort, serum uric acid was an independent risk factor for all HF and fatal HF (31). A study conducted in Japan showed that elevated uric acid levels were associated with a higher incidence of the primary endpoint and rehospitalization owing to acute decompensated HF (32). Cicero et al. (33) found that hyperuricemia is an emerging risk factor in the pathogenesis of HF and is intricately linked to a bleaker prognosis in HF patients. In a meta-analysis, the author found that elevated serum uric acid levels independently predicted all-cause mortality and the combined endpoint of death or readmission in acute HF patients (34). In the study by Coiro et al., Elevated serum uric acid concentrations have incremental prognostic value in elderly patients with acute HF, regardless of etiology and systolic function (36). The result from a comprehensive meta-analysis revealed that higher serum uric acid levels were associated with an increased risk of all-cause mortality, cardiac death, and HF rehospitalization in HF patients (15). However, the prognostic value of serum uric acid level in patients with HFpEF has not been fully elucidated. Our findings indicate that elevated serum uric acid levels were associated with an increased risk of all-cause, CV mortality, and HF hospitalization in patients with HFpEF. In a study investigating whether serum uric acid level on admission could be associated with subsequent mortality in hospitalized patients with HFpEF, higher admission serum uric acid was an independent determinant of mortality in hospitalized HFpEF patients (25). In the study by Nishino et al. (21), uric acid was a predictor for the composite of all-cause death and HF re-hospitalization in patients with hyperuricemia and HFpEF. In hospitalized elderly patients with chronic HF, serum uric acid was an independent predictor of adverse outcomes, which can be seen in HFmrEF patients (37). In a study involving 210 patients with HFpEF, elevated serum uric acid was significantly associated with the HF readmission rate in patients with HFpEF (24). In a study conducted in China, uric acid level was associated with HF readmission in patients with HFpEF (38). Our findings suggest that elevated serum uric acid levels serve as a significant prognostic marker in patients with HFpEF, indicating a potential role in the pathophysiology of the disease and its clinical outcomes.
Several insights into the potential mechanisms by which lowering uric acid levels may improve outcomes in patients with HF were provided by previous studies. A systemic proinflammatory state induced by comorbidities, including hyperuricemia, could cause myocardial structural and functional alterations (39). Furthermore, elevated uric acid levels can trigger a systemic inflammatory response, predisposing to comorbidities such as infections and malignancies, which significantly contribute to the mortality rate in HFpEF (40). Elevated uric acid may lead to increased cytokine activation, insulin resistance and oxidative stress, impair endothelial function and activate the renin-angiotensin system (41–44). Uric acid may also directly contribute to HF worsening by elevating blood pressure (45), and reducing renal function (46).
In addition, HFpEF patients varied by LVEF have different clinical characteristics, prognosis, and treatment response (47, 48). In this study, HFpEF patients had differences in LVEF. Although the patients we included was mostly elderly, the age distribution was not uniform. Age-related mechanisms play an important role in the pathophysiology of HFpEF (49). Older patients are at higher risk of side effects from HF medications (50). The proportion of men and women in the studies we included was fairly evenly distributed. A previous study found that hyperuricemia was associated with HF readmission in all patients, especially men (24). This is consistent with the higher comorbidities burden in men with HF (51). The observed differences may suggest that the impact of serum uric acid levels in patients with HFpEF requires a more personalized approach, taking into account the specific conditions of each patient.
In this meta-analysis, the administration of uric acid-lowering therapy did not yield a statistically significant reduction in mortality rates among patients afflicted with HFpEF. However, it was observed that uric acid-lowering therapy was correlated with a decreased risk of HF hospitalization. A systematic review and meta-analysis of RCTs showed that uric acid-lowering therapies did not improve all-cause mortality and CV death in HF patients (52). A recent meta-analysis suggested that targeting uric acid-lowering as a therapeutic intervention did not improve the prognosis of patients with HF (15). However, a study enrolling patients with HFpEF from the Prospective Multicenter Observational Study of Patients With Heart Failure With Preserved Ejection Fraction (PURSUIT-HFpEF) registry suggested that comprehensive interventions for lowering uric acid, including the use of urate-lowering therapy, in patients with hyperuricemia and HFpEF can have an effect of beneficial prognosis (21). The conflicting results of these findings may be attributed to differences in uric acid-lowering therapies. In the study by Suzuki et al. (53), febuxostat was potentially more effective than allopurinol for treating patients with chronic HF and hyperuricemia. These findings suggest that while uric acid-lowering therapy may not improve mortality rates in HFpEF in this study, it could still play a role in managing the disease. Further research, including well-designed clinical trials, is needed to determine the impact of lowering uric acid therapies in patients with HFpEF.
The importance of our research lies in the following aspects. Firstly, this study underscores the importance of monitoring serum uric acid levels in patients with HFpEF as a marker for early identification of those at risk for adverse outcomes. By regularly assessing serum uric acid levels, clinicians can identify high-risk patients earlier and adjust treatment strategies promptly to prevent potential adverse outcomes. Secondly, the meta-analysis provides new guidance for clinical practice, suggesting that physicians should consider serum uric acid levels as a factor in management and treatment decisions for HFpEF patients. This may include more aggressive interventions for patients with hyperuricemia to mitigate the risk of adverse outcomes. Thirdly, the study also sets the stage for future research by exploring whether lowering serum uric acid levels could offer additional benefits for HFpEF patients and how personalized treatment plans can minimize the adverse outcomes of HF. This could involve larger-scale clinical trials to validate the efficacy of uric acid-lowering therapy and to determine the optimal therapeutic approaches and timing for such interventions.
The strengths of our study include several key aspects: Firstly, it is the first meta-analysis to explore the association between adverse outcomes and uric acid-lowering therapy in patients with HFpEF. Secondly, the study incorporated a substantial sample size from high-quality literature, which lends a degree of reliability and stability to the findings. Thirdly, subgroup analyses were conducted on outcomes related to all-cause mortality and HF hospitalization, stratifying the study population based on the presence of hyperuricemia, the defined range of LVEF, and the type of uric acid-lowering therapy used. However, there are limitations to consider: Firstly, initially, angiotensin receptor neprilysin inhibitors (ARNi) and SGLT2i are not specifically developed to lower uric acid levels. It is plausible that the amelioration of HF symptoms could secondarily result in decreased uric acid levels, as the resolution of HF can lead to improved renal function and reduced uric acid retention (54). Consequently, discerning whether the observed enhancements in HF prognosis are attributable to the direct pharmacological action of these drugs, or indirectly due to the amelioration of HF and its associated metabolic changes, remains a challenge. Secondly, there were different thresholds for defining hyperuricemia and hypouricemia across studies, which may influence the results and may be one of the sources of heterogeneity in the outcome measures. Thirdly, the limited number of studies reporting on certain outcomes may affect the stability of the findings. Fourth, our meta-analysis is unable to perform a formal assessment of publication bias using funnel plots for the outcomes evaluated. Commonly, funnel plots are utilized to detect potential publication bias when a sufficient number of studies—typically ten or more are available for an outcome. This graphical method aids in visualizing the distribution of study results and identifying any asymmetry that may suggest selective reporting or publication of results. In our analysis, each outcome was represented by fewer than ten studies, which limits the reliability of funnel plot analysis to detect publication bias. These limitations should be taken into account when interpreting the results and when designing future research to further investigate the role of uric acid levels and uric acid-lowering therapy in HFpEF patients.
Conclusion
In summary, these results underscore the importance of serum uric acid levels in the prognosis of HFpEF and the potential utility of uric acid-lowering therapy in reducing HF hospitalization, while also highlighting the need for further research to clarify whether interventions targeting hyperuricemia can confer benefits to HFpEF patients.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author contributions
LL: Conceptualization, Methodology, Project administration, Supervision, Writing – original draft. YC: Data curation, Formal Analysis, Investigation, Methodology, Writing – review & editing. FL: Data curation, Formal Analysis, Investigation, Methodology, Writing – review & editing. YY: Conceptualization, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2024.1403242/full#supplementary-material
References
1.
SavareseGBecherPMLundLHSeferovicPRosanoGMCCoatsAJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. (2023) 118(17):3272–87. 10.1093/cvr/cvac013
2.
DesaiASLamCSPMcMurrayJJVRedfieldMM. How to manage heart failure with preserved ejection fraction: practical guidance for clinicians. JACC Heart Fail. (2023) 11(6):619–36. 10.1016/j.jchf.2023.03.011
3.
BorlaugBASharmaKShahSJHoJE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. (2023) 81(18):1810–34. 10.1016/j.jacc.2023.01.049
4.
RedfieldMMBorlaugBA. Heart failure with preserved ejection fraction: a review. JAMA. (2023) 329(10):827–38. 10.1001/jama.2023.2020
5.
OmoteKVerbruggeFHBorlaugBA. Heart failure with preserved ejection fraction: mechanisms and treatment strategies. Annu Rev Med. (2022) 73:321–37. 10.1146/annurev-med-042220-022745
6.
ReddyYNVRikhiAObokataMShahSJLewisGDAbouEzzedineOFet alQuality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. (2020) 22(6):1009–18. 10.1002/ejhf.1788
7.
PfefferMAShahAMBorlaugBA. Heart failure with preserved ejection fraction in perspective. Circ Res. (2019) 124(11):1598–617. 10.1161/circresaha.119.313572
8.
AnkerSDButlerJFilippatosGFerreiraJPBocchiEBöhmMet alEmpagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. (2021) 385(16):1451–61. 10.1056/NEJMoa2107038
9.
SolomonSDMcMurrayJJVClaggettBde BoerRADeMetsDHernandezAFet alDapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. (2022) 387(12):1089–98. 10.1056/NEJMoa2206286
10.
SaitoYTanakaANodeKKobayashiY. Uric acid and cardiovascular disease: a clinical review. J Cardiol. (2021) 78(1):51–7. 10.1016/j.jjcc.2020.12.013
11.
CarluccioECoiroSAmbrosioG. Unraveling the relationship between serum uric acid levels and cardiovascular risk. Int J Cardiol. (2018) 253:174–5. 10.1016/j.ijcard.2017.11.035
12.
MiaoLGuoMPanDChenPChenZGaoJet alSerum uric acid and risk of chronic heart failure: a systematic review and meta-analysis. Front Med (Lausanne). (2021) 8:785327. 10.3389/fmed.2021.785327
13.
DialloADialloMFCarlos-BolumbuMGaltierF. Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: a systematic review and meta-analysis. Diabetes Obes Metab. (2024) 26(5):1980–5. 10.1111/dom.15483
14.
KanbayMAfsarBSiriopolDDincerNErdenNYilmazOet alEffect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies. Angiology. (2020) 71(4):315–23. 10.1177/0003319719897509
15.
QinSXiangMGaoLChengXZhangD. Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis. ESC Heart Fail. (2024) 11(1):78–90. 10.1002/ehf2.14535
16.
PageMJMcKenzieJEBossuytPMBoutronIHoffmannTCMulrowCDet alThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J (2021) 372:n71. 10.1136/bmj.n71
17.
StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25(9):603–5. 10.1007/s10654-010-9491-z
18.
OremusMOremusCHallGBMcKinnonMC. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa scales. BMJ Open. (2012) 2(4):e001368. 10.1136/bmjopen-2012-001368
19.
ShimizuTYoshihisaAKannoYTakiguchiMSatoAMiuraSet alRelationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction. Am J Physiol Heart Circ Physiol. (2015) 309(7):H1123–9. 10.1152/ajpheart.00533.2015
20.
SelvarajSClaggettBLPfefferMADesaiASMc CauslandFRMcGrathMMet alSerum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. (2020) 22(11):2093–101. 10.1002/ejhf.1984
21.
NishinoMEgamiYKawanamiSSugaeHUkitaKKawamuraAet alLowering uric acid may improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction. J Am Heart Assoc. (2022) 11(19):e026301. 10.1161/jaha.122.026301
22.
AmbrosioGLeiroMGCLundLHCoiroSCardonaAFilippatosGet alSerum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: analysis of the ESC-EORP heart failure long-term (HF LT) registry. Eur J Intern Med. (2021) 89:65–75. 10.1016/j.ejim.2021.04.001
23.
CarnicelliAPClareRChiswellKLytleBBjursellMPerlSet alComparison of characteristics and outcomes of patients with heart failure with preserved ejection fraction with versus without hyperuricemia or gout. Am J Cardiol. (2020) 127:64–72. 10.1016/j.amjcard.2020.04.026
24.
DengXLYiHWXiaoJZhangXFZhaoJSunMet alSerum uric acid: a risk factor for right ventricular dysfunction and prognosis in heart failure with preserved ejection fraction. Front Endocrinol (Lausanne). (2023) 14:1143458. 10.3389/fendo.2023.1143458
25.
KobayashiYOmoteKNagaiTKamiyaKKonishiTSatoTet alPrognostic value of serum uric acid in hospitalized heart failure patients with preserved ejection fraction (from the Japanese nationwide multicenter registry). Am J Cardiol. (2020) 125(5):772–6. 10.1016/j.amjcard.2019.12.003
26.
WangCCheHBZhouYWangRQZhuDChengLTet alJoint association of hyperuricemia and chronic kidney disease with mortality in patients with chronic heart failure. Front Endocrinol (Lausanne). (2023) 14:1131566. 10.3389/fendo.2023.1131566
27.
SolomonSDMcMurrayJJVAnandISGeJLamCSPMaggioniAPet alangiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. (2019) 381(17):1609–20. 10.1056/NEJMoa1908655
28.
AnkerSDButlerJUsmanMSFilippatosGFerreiraJPBocchiEet alEfficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of emperor-preserved. Nat Med. (2022) 28(12):2512–20. 10.1038/s41591-022-02041-5
29.
NassifMEWindsorSLBorlaugBAKitzmanDWShahSJTangFMet alThe SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. (2021) 27(11):1954. 10.1038/s41591-021-01536-x
30.
MálekFOšťádalPPařenicaJJarkovskýJVítovecJWidimskýPet alUric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the acute heart failure database registry. J Crit Care. (2012) 27(6):737.e11–24. 10.1016/j.jcrc.2012.03.011
31.
MuiesanMLSalvettiMVirdisAMasiSCasigliaETikhonoffVet alSerum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the uric acid right for heart health study. J Hypertens. (2021) 39(1):62–9. 10.1097/hjh.0000000000002589
32.
YamamotoHNagatomoYMaharaKYoshikawaT. In-hospital serum uric acid change predicts adverse outcome in patients with heart failure. J Card Fail. (2020) 26(11):968–76. 10.1016/j.cardfail.2020.07.002
33.
CiceroAFGCosentinoERKuwabaraMDegli EspostiDBorghiC. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. (2019) 14(6):949–56. 10.1007/s11739-019-02070-y
34.
HuangGQinJDengXLuoGYuDZhangMet alPrognostic value of serum uric acid in patients with acute heart failure: a meta-analysis. Medicine (Baltimore). (2019) 98(8):e14525. 10.1097/md.0000000000014525
35.
HuangHHuangBLiYHuangYLiJYaoHet alUric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. (2014) 16(1):15–24. 10.1093/eurjhf/hft132
36.
CoiroSCarluccioEBiagioliPAlunniGMurroneAD’AntonioAet alElevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. Nutr Metab Cardiovasc Dis. (2018) 28(4):361–8. 10.1016/j.numecd.2017.12.009
37.
YanWTangHYYangYQHeKL. Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes. BMC Cardiovasc Disord. (2023) 23(1):589. 10.1186/s12872-023-03544-w
38.
LiuXHuangGYouYZhangYWangTZhuYet alHyperuricemia is associated with heart failure readmission in patients with heart failure and preserved ejection fraction-an observational study in Chinese. Nutr Metab Cardiovasc Dis. (2024) 34(2):521–8. 10.1016/j.numecd.2023.10.019
39.
PaulusWJTschöpeC. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. (2013) 62(4):263–71. 10.1016/j.jacc.2013.02.092
40.
NishinoMYanoMUkitaKKawamuraANakamuraHMatsuhiroYet alImpact of readmissions on octogenarians with heart failure with preserved ejection fraction: pursuit-HFpEF registry. ESC Heart Fail. (2021) 8(3):2120–32. 10.1002/ehf2.13293
41.
GaoKLiYSuYLinZYangXXuMet alHigh uric acid promotes mitophagy through the ROS/CaMkIIδ/parkin pathway in cardiomyocytes in vitro and in vivo. Am J Transl Res. (2021) 13(8):8754–65. PMID: ; PMCID: PMC8430116
42.
KimuraYYanagidaTOndaATsukuiDHosoyamadaMKonoH. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol. (2020) 40(3):570–82. 10.1161/atvbaha.119.313224
43.
SunXJiaoHZhaoJWangXLinH. Unexpected effect of urate on hydrogen peroxide-induced oxidative damage in embryonic chicken cardiac cells. Free Radic Res. (2017) 51(7-8):693–707. 10.1080/10715762.2017.1362106
44.
ZhiLYuzhangZTianliangHHisatomeIYamamotoTJidongC. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS One. (2016) 11(2):e0147737. 10.1371/journal.pone.0147737
45.
FeigDIKangDHJohnsonRJ. Uric acid and cardiovascular risk. N Engl J Med. (2008) 359(17):1811–21. 10.1056/NEJMra0800885
46.
KangDHNakagawaTFengLWatanabeSHanLMazzaliMet alA role for uric acid in the progression of renal disease. J Am Soc Nephrol. (2002) 13(12):2888–97. 10.1097/01.asn.0000034910.58454.fd
47.
GuJKeJHWangYWangCQZhangJF. Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction. Front Cardiovasc Med. (2022) 9:944441. 10.3389/fcvm.2022.944441
48.
RoschSKresojaKPBeslerCFenglerKSchöberARvon RoederMet alCharacteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation. (2022) 146(7):506–18. 10.1161/circulationaha.122.059280
49.
GharagozlooKMehdizadehMHeckmanGRoseRAHowlettJHowlettSEet alHeart failure with preserved ejection fraction in the elderly: basic mechanisms and clinical considerations. Can J Cardiol. S0828-282X(24)00302-7. (2024). 10.1016/j.cjca.2024.04.006. [Epub ahead of print]
50.
ElkammashATamSSCYogarajahGYouJ. Management of heart failure with preserved ejection fraction in elderly patients: effectiveness and safety. Cureus. (2023) 15(2):e35030. 10.7759/cureus.35030
51.
LauESCunninghamTHardinKMLiuEMalhotraRNayorMet alSex differences in cardiometabolic traits and determinants of exercise capacity in heart failure with preserved ejection fraction. JAMA Cardiol. (2020) 5(1):30–7. 10.1001/jamacardio.2019.4150
52.
XuHLiuYMengLWangLLiuD. Effect of uric acid-lowering agents on patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Front Cardiovasc Med. (2021) 8:639392. 10.3389/fcvm.2021.639392
53.
SuzukiSYoshihisaAYokokawaTKobayashiAYamakiTKuniiHet alComparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. (2021) 49(12):3000605211062770. 10.1177/03000605211062770
54.
TownsendNWilsonLBhatnagarPWickramasingheKRaynerMNicholsM. Corrigendum to: cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J (2019) 40(2):189. 10.1093/eurheartj/ehy342
Summary
Keywords
serum uric, uric acid lowering therapy, heart failure with preserved ejection fraction, meta-analysis, relationship
Citation
Li L, Chang Y, Li F and Yin Y (2024) Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis. Front. Cardiovasc. Med. 11:1403242. doi: 10.3389/fcvm.2024.1403242
Received
19 March 2024
Accepted
29 May 2024
Published
13 June 2024
Volume
11 - 2024
Edited by
Erberto Carluccio, Heart Failure Unit, Italy
Reviewed by
Stefano Coiro, Hospital of Santa Maria della Misericordia in Perugia, Italy
Akito Nakagawa, Nakagawa Clinic, Japan
Updates
Copyright
© 2024 Li, Chang, Li and Yin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuehui Yin yhyincardiology@hotmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.